Clinical Trial Update: A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study) [Phase 3]

View source ↗

Summary

A Phase 3 trial of Alegitazar in patients with Type 2 diabetes mellitus and chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Alegitazar

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2, Kidney Disease, Chronic | Phase 3 | Status: WITHDRAWN